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Abstract
The surface of the mature dengue virus (DENV) particle consists of 90 envelope (E) protein dimers that mediate both receptor binding and
fusion. The E protein ectodomain can be divided into three structural domains designated ED1, ED2, and ED3, of which ED3 contains the critical
and dominant virus-specific neutralization sites. In this study the ED3 epitopes recognized by seven, murine, IgG1 DENV-2 type-specific,
monoclonal antibodies (MAbs) were determined using site-directed mutagenesis of a recombinant DENV-2 ED3 (rED3) protein. A total of 41
single amino acid substitutions were introduced into the rED3 at 30 different surface accessible residues. The affinity of each MAb with the mutant
rED3s was assessed by indirect ELISA and the results indicate that all seven MAbs recognize overlapping epitopes with residues K305 and P384
critical for binding. These residues are conserved among DENV-2 strains and cluster together on the upper lateral face of ED3. A linear
relationship was observed between relative occupancy of ED3 on the virion by MAb and neutralization of the majority of virus infectivity (∼90%)
for all seven MAbs. Depending on the MAb, it is predicted that between 10% and 50% relative occupancy of ED3 on the virion is necessary for
virus neutralization and for all seven MAbs occupancy levels approaching saturation were required for 100% neutralization of virus infectivity.
Overall, the conserved antigenic site recognized by all seven MAbs is likely to be a dominant DENV-2 type-specific, neutralization determinant.
© 2007 Elsevier Inc. All rights reserved.Keywords: Dengue; Flavivirus; Envelope protein domain III; Neutralization; Monoclonal antibodiesIntroduction
Dengue (DEN) is the most important mosquito-borne viral
disease in terms of the number of cases each year and its
geographic distribution. It is estimated that 2.5 billion people
are at risk for DEN worldwide, with 50–100 million infections
each year, including 250,000–500,000 cases of dengue
hemorrhagic fever (DHF) (Halstead, 1988; Monath, 1994).
DEN is a disease caused by four genetically and antigenically
related viruses termed DENV-1, DENV-2, DENV-3, and
DENV-4. There is extensive antigenic cross-reactivity between
the DEN viruses but only limited, short-term, cross-protective
immunity in humans (Sabin, 1952). Consequently, humans can
have four separate DENV infections.⁎ Corresponding author.
E-mail address: abarrett@utmb.edu (A.D.T. Barrett).
0042-6822/$ - see front matter © 2007 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2007.05.042The DENV are members of the genus Flavivirus, family
Flaviviridae, and have a positive-sense, single-stranded, RNA
genome of approximately 11 kb in length (Chambers et al.,
1990). They have a relatively simple enveloped virion that is
50 nm in diameter and consists of a capsid protein (C),
membrane protein (M), and a major envelope glycoprotein (E)
(Kuhn et al., 2002). The surface of the mature DENV virus
particle consists of 90 E protein dimers (Kuhn et al., 2002;
Zhang et al., 2003) that mediate both receptor binding (Crill and
Roehrig, 2001) and fusion (Allison et al., 1995, 2001; Heinz
and Allison, 2000).
The E protein is approximately 500 amino acids in length of
which the N-terminal 400 amino acids form the ectodomain.
The E protein ectodomain can be divided into three structural
domains designated domain I, domain II, and domain III (ED1,
ED2, and ED3, respectively) (Modis et al., 2003). ED1 is
centrally located in the folded monomer, while ED2 is involved
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mature virion. ED2 also contains the fusion peptide, which is
necessary for low-pH triggered fusion with the endosomal
membrane and release of viral RNA into the cell cytoplasm
(Allison et al., 2001). ED3 has an immunoglobulin-like fold,
which is characteristic of many cell receptors. In addition, the
flavivirus ED3 contains the critical and dominant virus-specific
neutralization site(s) (Roehrig, 2003). In terms of the DENVs,
ED3 elicits neutralizing antibodies that are predominantly
DENV type-specific and are the most effective in terms of
blocking virus adsorption to susceptible cells (Crill and
Roehrig, 2001; Hung et al., 1999). Thus, ED3 has been impli-
cated as the primary receptor-binding motif.
Compared to other flaviviruses, there has been relatively
little work reported on fine mapping of neutralizing epitopes for
DENV. DENV-2 neutralizing antibodies have been mapped to
ED2, near the fusion loop, and ED3 (Roehrig et al., 1998).
Some DENV neutralizing epitopes have been mapped to
specific amino acids within ED3 by generating monoclonal
antibody (MAb) resistant variants for DENV-2 (Hiramatsu et al.,
1996; Lin et al., 1994; Lok et al., 2001) and DENV-3 (Serafin
and Aaskov, 2001), but none for DENV-1 or DENV-4.
Trirawatanapong et al. (1992) used overlapping peptides of
ED3 to map the epitope of DENV-2 type-specific MAb 3H5 to
amino acids 386–397 of the E protein. These results differed
from those of Roehrig et al. (1990) who used similar peptides,
derived from DENV-2 strain Jamaica 83, for epitope mapping
and found that a peptide from amino acids 388–400 did not bind
to MAb 3H5. Interestingly, the epitope mapped by Trirawata-
napong et al. (1992) is adjacent, in the linear sequence of E, to
the epitope mapped by Hiramatsu et al. (1996) (residues 383–
385 of ED3) using mutagenesis of a DENV infectious clone.
Peptides of ED3 have also been used to map a DENV complex
MAb, 4E11, to a linear epitope consisting of residues 306–314
of the E protein (Thullier et al., 2001).
All of the above epitope mapping studies for DENV report
linear epitopes or epitopes that consist of single amino acids.Fig. 1. Western blot of anti-DENV-2 monoclonal antibodies. The non-reducing protei
lanes are (1) rainbow marker, (2) “uninduced” bacterial extract, and (3) “induced” DE
showing recognition of the DENV-2 MBP-rED3 by MAbs (A) 3H5, (B) M8051122,
MAbs recognize the approximately 50 kDa DENV-2 MBP-rED3 fusion protein.However, structural studies of antibodies in complex with ED3s
from two other flaviviruses, Japanese encephalitis virus (JEV)
(Wu et al., 2003) and West Nile virus (WNV) (Kaufmann et al.,
2006; Nybakken et al., 2005), revealed that there are several
amino acid contacts at the binding interface between the
antibody and ED3, and these amino acids form conformational
epitopes. Thus, a more thorough analysis of DENV neutralizing
epitopes will provide a better understanding of the molecular
mechanism of DENV neutralization and aid in the development
of candidate DENV vaccines.
In this study the epitopes recognized by seven DENV-2 type-
specific MAbs were determined using site-directed mutagenesis
of a recombinant DENV-2 ED3 (rED3) protein. The results
indicate that all seven MAbs recognize a similar antigenic site
that is conserved among DENV-2 strains and is located on the
upper lateral face of ED3. Also, a comparison of plaque
reduction neutralization (PRNT) curves and ELISA binding
curves using whole DENV-2 virions as antigen indicates that
there is a linear relationship between relative occupancy of this
antigenic site on ED3 by MAb and neutralization of the
majority of virus infectivity. These data will be valuable for the
rationale design of a DENV-2 vaccine that elicits antibodies
against this highly conserved antigenic site.
Results
Characterization of MAbs
All seven MAbs (3H5, M8051122, 9F16, 2Q1899, 1P-05-
143, GTX77558, and 5C36) were shown to recognize the
DENV-2 strain New Guinea C (NGC) rED3 byWestern blotting
(Fig. 1) and were shown to be specific for DENV-2 by indirect
ELISA with rED3s from DENV-1 strain OBS7690, DENV-2
strain NGC, DENV-3 strain H87, and DENV-4 strain 703-4,
with MBP used as a negative control (Fig. 2). The Kd of all
seven MAbs was determined for the DENV-2 NGC rED3 by
titration in an indirect ELISA, as described in Materials andn gel, shown in lanes 1, 2, and 3, was stained with brilliant blue and in each of the
NV-2 MBP-rED3 bacterial extract. Lanes A to G are non-reducing Western blots
(C) 9F16, (D) 2Q1899, (E) IP-05-143, (F) GTX77558, and (G) 5C36. All seven
Fig. 2. ELISA showing the reactivity of the seven DENV-2 ED3 specific MAbs and DENV-2 MIAF with DENV-1, -2, -3, and -4 MBP-tagged rED3s and negative
control MBP. MAbs were tested at a concentration 50-fold higher than their Kd for the DENV-2 NGC MBP-rED3. Equal loading for each of the proteins was
confirmed with anti-MBP serum (data not shown). The error bars represent the standard deviation.
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rED3 with Kds ranging from 0.9 nM to 4.3 nM (Table 1).
Statistically significant differences in Kd values were seen
between MAbs 3H5 and GTX77558, 3H5 and IP-05-143, as
well as 2Q1899 and GTX77558.
To determine if the affinity of each MAb for the rED3 was
similar to the affinity for virion-associated ED3, the Kd of each
MAb was determined by titration in an indirect ELISA using
purified DENV-2 NGC virus as antigen. The affinity of each
MAb for the virion-associated ED3 was nearly identical to the
affinity for the rED3, with Kd values ranging from 0.9 nM to
7.2 nM (Table 1). There were no statistically significant
differences in Kd values between MAbs or between the Kd
values for virion-associated ED3 and rED3 for each MAb. This
indicates that the presentation of the rED3 bound to the solidTable 1
Properties of DENV-2 MAbs
MAb clone Isotype DENV-2 strain
raised against
DENV rED3
specificity
3H5 IgG1 NGC 2
M8051122 IgG1 NGC 2
9F16 IgG1 NGC 2
2Q1899 IgG1 NGC 2
IP-05-143 IgG1 Unknown 2
GTX77558 IgG1 Unknown 2
5C36 IgG1 Unknown 2
a There was a statistically significant difference between the Kd with rED3 and th
b There was a statistically significant difference between the Kd with rED3/virusphase is equivalent to what is presented by virion-associated
ED3.
A neutralization assay (using PRNT50) was undertaken for
each of the seven MAbs with DENV-2 strain NGC to deter-
mine the concentration of MAb required to obtain a 50%
reduction in virus infectivity. The PRNT50 concentrations
ranged from 1.5 nM to 11.6 nM for all seven MAbs (Table 1).
MAb 5C36 had a statistically significant difference in PRNT50
concentration compared to the other six MAbs. This MAb
required a slightly higher concentration (2-fold to 8-fold higher
compared to the other six MAbs) to achieve a 50% reduction
in virus infectivity. This observation did not correlate with
the affinity of MAb 5C36 for rED3 or virion-associated ED3
as there was no statistical difference in affinity from the other
6 MAbs.Kd with DENV-2
NGC rED3 (nM)
Kd with DENV-2
NGC virus (nM)
PRNT50 concentration
(DENV-2 NGC) (nM)
4.3±0.7 2.8±0.1 4.6±0.8
2.5±0.3 4.1±1.1 3.6±0.4
3.2±0.3 4.1±0.7 5.2±0.8
4.0±0.5 7.2±2.1 5.4±0.5
1.8±0.2 a 3.0±0.5 5.0±0.6 a
0.9±0.1 0.9±0.4 1.5±0.2
2.2±0.2 b 3.9±0.3 b 11.6±1.2 b
e PRNT50 concentration for MAb IP-05-143.
and PRNT50 concentration for MAb 5C36.
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MAb 3H5 was used, as an example, to examine the ability of
a DENV-2 ED3 type-specific MAb to neutralize multiple
DENV-2 strains. A total of five DENV-2 strains (NGC,
DAKHD10674, DAKAR578, H8-2027, and IB-H11208) were
tested in a PRNT50 assay. MAb 3H5 effectively neutralized all
five strains with PRNT50 concentrations ranging from 2.3 nM to
7.4 nM (Table 2). There was no statistically significant
difference between the PRNT50 concentrations of any of the
DENV-2 strains compared to DENV-2 NGC.
Occupancy of ED3 on the virion and neutralization of
infectivity
According to the law of mass action, the relative occupancy
is a function of the dissociation constant, Kd, and the
concentration of un-complexed MAb. In both the ELISA and
PRNTassays there was a molar excess of MAb. To illustrate this
point, even if all of the approximately 5×104 PFU (i.e. virions)
were capable of being bound to the wells in the ELISA plate, the
molar ratio of MAb to virion-associated ED3 would still be
about 130 at the lowest dilution of MAb used. This ratio would
be at least two orders of magnitude higher with the 100 PFU
used in the PRNT assays. Under these conditions, the
complexed MAb becomes negligible and therefore the
concentration of un-complexed MAb remains relatively con-
stant. Therefore, the fractional occupancy as predicted by the
ELISA using purified virus as antigen can be translated to the
fractional occupancy of ED3 on virions by MAb in the PRNT
assay (see Materials and methods).
For each MAb, the ELISA binding data with purified virus
as antigen were translated to percent relative occupancy (see
Materials and methods) and was compared to the curve of
percent neutralization of virus infectivity as a function of MAb
concentration. As examples, this comparison is shown for
MAbs 3H5 and 5C36 (Figs. 3a and b, respectively). For MAb
3H5 the curve for relative occupancy of ED3 on the virion as
a function of MAb concentration had a slope factor of −1.0±
0.0 and a Kd value of 2.8±0. 1 nM (Fig. 3a). By contrast, the
curve for percent neutralization of virus infectivity as a
function of MAb concentration had a slope factor of −1.5±0.4
and a PRNT50 concentration of 4.6±0.8 nM (Fig. 3a). For
Mab 5C36, the curve for relative occupancy of ED3 on the
virion as a function of MAb concentration had a slope factor
of −1.0±0.0 and a Kd value of 3.9±0.3 nM (Fig. 3b). ByTable 2
PRNT50 concentrations of various DENV-2 strains with MAb 3H5
DENV-2 Strain Host Year isolated Country
NGC Human 1944 New Gu
DAKHD10674 Human 1970 Senegal
DAKAR578 Mosquito 1980 Ivory C
H8-2027 Human Unknown Malaysi
IB-H11208 Human 1966 Nigeria
a ND: not determined.contrast, the curve for percent neutralization of virus infectivity
as a function of MAb concentration had a slope factor of −2.0±
0.4 and a PRNT50 concentration of 11.6±1.2 nM (Fig. 3b). The
fact that the curves for physical binding and neutralization have
different slopes indicates that neutralization of virus infectivity
is correlated with, but not directly proportional to, MAb
occupancy of ED3. A similar relationship between relative
occupancy of ED3 on the virion and neutralization of virus
infectivity was seen for the other five Mabs as well (curves not
shown). For all the MAbs the data for binding to virion-
associated ED3 were best fit by a standard ligand binding curve
with a slope factor of −1.0 and the Kds for these curves are
listed in Table 1. The data for neutralization of infectivity by all
of the MAbs were best fit by dose–response curves having a
variable slope factor, which in all cases was steeper than the
slope factor for the curve of MAb binding to virion-associated
ED3. The slope factors for neutralization were −1.5±0.3 for
MAbM8051122, −1.4±0.3 for MAb 9F16, −2.2±0.4 for MAb
2Q1899, −1.6±0.3 for MAb IP-05-143, and −1.9±0.4 for
MAb GTX77558. The PRNT50 concentrations for these MAbs
are reported in Table 1.
The data for all seven MAbs were also plotted with percent
neutralization of virus infectivity as a function of percent
relative occupancy of ED3 on the virion. For all seven MAbs
there was a linear relationship between the relative occupancy
of ED3 required to neutralize the majority of virus infectivity
(∼90%). The data were fit by a line (R2N0.98) and as examples
MAb 3H5 is shown in Fig. 3c and MAb 5C36 in Fig. 3d. For
MAb 3H5, the equation for the line is y=1.43x−35.65, where
y=“percent neutralization of virus infectivity” and x=“percent
relative occupancy of ED3 on the virion by MAb.” Using this
model for MAb 3H5, it is predicted that at approximately 32%,
60%, and 88% occupancies of ED3 by MAb the percent
neutralization of virus infectivity will be approximately 10%,
50%, and 90%, respectively (Fig. 3c). In addition, a threshold
for neutralization is predicted from this model at approximately
25% occupancy of ED3 by MAb 3H5 (Fig. 3c). The results
were strikingly different when the same analysis was done for
MAb 5C36. It is predicted that at approximately 55%, 75%, and
94% occupancies of ED3 by MAb 5C36 the percent
neutralization of virus infectivity will be approximately 10%,
50%, and 90%, respectively (Fig. 3d). In addition, a threshold
for neutralization is predicted from this model at approximately
50% occupancy of ED3 by MAb 5C36 (Fig. 3d). The same
analysis was done for the other five MAbs and estimates of
percent relative occupancy predicted to neutralize variouswhere isolated Genotype PRNT50 concentration (nM)
inea Asian 2 4.6±0.8
Sylvatic 5.1±0.7
oast Sylvatic 7.4±0.4
a NDa 4.3±0.9
NDa 2.3±0.1
Table 3
Estimates of percent relative occupancy of ED3 on the virion by MAb required
to neutralize various percentages of virus infectivity
MAb Percent relative occupancy of ED3 on virion by MAb
predicted to result in a percent neutralization of virus
infectivity of
0% (threshold) a 10% 50% 90%
3H5 25% 32% 60% 88%
M8051122 10% 18% 51% 84%
9F16 15% 23% 55% 87%
2Q1899 16% 22% 46% 70%
IP-05-1432 28% 35% 60% 85%
GTX77558 31% 38% 64% 90%
5C36 50% 55% 75% 94%
a Percent relative occupancy levels greater than the threshold value are
predicted to neutralize virus infectivity.
Fig. 3. Relationship between occupancy of ED3 binding sites and neutralization of virus infectivity using MAbs 3H5 and 5C36 as examples. Panels a and b are graphs
comparing the percent relative occupancy of available ED3 binding sites on the DENV-2 virion by MAb and the percent neutralization of virus infectivity as a function
of the concentration of MAb. As the occupancy of ED3 approaches saturation the percent neutralization of infectivity approaches 100%. The relative occupancy curves
for both MAb 3H5 and MAb 5C36 have slope factors of −1.0±0.0 whereas the neutralization curves have slope factors of −1.5±0.4 for MAb 3H5 and −2.0±0.4 for
MAb 5C36. This indicates that occupancy and neutralization are correlated, but not proportionally. Panels c and d show the percentage of virus infectivity neutralized
as a function of the percent relative occupancy of ED3 binding sites on the virion for MAbs 3H5 and 5C36. There is a linear relationship between occupancy and
neutralization of the majority of virus infectivity (∼90%) for both MAbs and from this model it is predicted that relative occupancies of N25% for MAb 3H5 or
N50% for MAb 5C36 are necessary for virus neutralization.
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widest range of relative occupancy values between MAbs was
seen for the estimated thresholds of neutralization. MAbs that
deviated furthest from the mean of 25%±5% relative occu-
pancy were M8051122 and 5C36, having thresholds for virus
neutralization estimated at 10% and 50% respectively. The
mean for 10% neutralization of virus infectivity was 32%±5%
relative occupancy and MAbs M8051122 and 5C36 differed the
most from the mean with an estimated relative occupancy of
18% and 55%, respectively. The mean for 50% neutralization of
virus infectivity was 59%±3% relative occupancy with MAbs
2Q1899 and 5C36 deviating the most with estimated occupan-
cies of 46% and 75%, respectively. The narrowest range of
occupancy values between MAbs was seen for 90% neutraliza-
tion of virus infectivity. The mean was 86%±3% relative
occupancy and MAbs 2Q1899 and 5C36 deviated the most,
Table 4
Relative dissociation constants of mutant rED3s compared to wild-type (Wt)
NGC rED3 with all MAb/rED3 mutant combinations
rED3 DENV-2 Type-specific MAb
3H5 M8051122 9F16 2Q1899 IP-05-143 GTX77558 5C36
Wt 1.0 1.0 1.0 1.0 1.0 1.0 1.0
K295G 0.4 0.7 2.3 1.1 0.6 1.1 0.7
S298G 0.4 0.4 0.5 0.9 1.1 1.5 0.9
Y299I 0.5 0.4 0.5 0.9 1.0 1.3 1.0
S300L 0.9 0.7 1.0 2.0 0.9 1.3 0.9
M301G ≥19 ≥32 ≥25 ≥20 ≥45 ≥47 20.0
M301A 1.5 2.4 1.8 1.9 2.5 4.5 2.7
T303G 1.0 0.7 0.7 1.4 1.2 2.2 1.2
K305G 13.0 16.0 ≥25 ≥20 14.0 ≥47 15.0
K305A ≥19 31.0 ≥25 ≥20 ≥45 ≥47 ≥72
K307G 1.1 1.2 4.4 3.3 1.5 2.1 1.8
V309G 1.4 1.0 1.1 1.8 1.3 2.1 1.0
K310E 0.3 0.6 1.6 0.9 0.7 0.7 0.5
E311G 0.7 0.6 0.6 1.7 0.8 1.5 0.9
E327G 0.5 0.6 4.2 1.5 1.0 1.5 0.5
D329E 4.1 2.5 2.1 3.6 0.9 1.4 1.2
D329G 0.6 0.6 4.5 0.9 0.9 0.7 0.5
G330D 0.4 0.4 0.4 0.7 0.8 1.1 0.5
S331A 0.3 0.6 1.4 1.0 1.0 1.1 0.7
S331P 2.2 1.3 1.2 2.2 0.9 1.1 1.1
P332G 7.1 3.0 2.6 6.6 2.1 4.2 3.1
P332A 5.4 1.3 0.9 0.2 0.5 6.3 4.9
K334Q 0.3 0.6 1.2 1.1 1.0 1.1 0.5
E338G 1.2 0.8 1.0 2.9 1.0 1.8 1.0
K344N 1.5 1.0 1.2 2.2 1.0 1.1 1.1
R345K 0.4 0.6 1.4 0.6 0.8 0.8 1.2
R345G 1.4 1.0 1.0 3.5 0.9 1.2 1.2
T359I 1.8 1.0 0.9 0.7 0.8 0.7 1.1
T359G 1.3 1.0 0.9 3.1 0.9 1.2 1.1
E360G 0.4 0.5 1.6 0.9 0.6 0.6 0.4
K361G 0.8 0.8 1.7 1.8 0.8 1.2 0.7
D362G 0.5 0.6 1.2 0.6 0.9 0.7 0.5
S363R 0.4 0.6 0.9 0.6 0.9 1.0 0.6
E383G ≥19 12.0 ≥25 ≥20 ≥45 ≥47 19.0
E383A 0.9 0.9 0.8 1.4 0.7 0.4 1.4
P384G ≥19 ≥32 ≥25 ≥20 ≥45 ≥47 20.0
P384A ≥19 ≥32 ≥25 ≥20 ≥45 ≥47 ≥72
G385E 0.5 0.6 0.6 0.9 0.8 0.8 0.6
K388G 2.6 1.0 3.7 3.3 1.5 1.7 0.5
N390D 0.9 0.8 1.1 2.1 0.9 1.5 0.6
N390H 0.6 0.4 1.1 1.4 0.5 0.3 0.8
N390S 0.8 0.7 0.8 1.8 1.0 1.6 0.8
Significant changes in binding affinity relative to Wt are shown in bold.
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respectively.
Binding affinity of MAbs with rED3 mutants
A total of 41 single amino acid substitutions were intro-
duced into the rED3 at 30 different surface accessible residues
(Table 4). Surface accessibility was determined by examining
the crystal structure of the DENV-2 E protein dimer (PDB-ID:
1OKE) (Modis et al., 2003). The solvent accessible surface
area was calculated for individual residues from 295 to 395 of
the DENV-2 ED3 using the program GETAREA 1.1 (Fraczkie-
wicz and Braun, 1998). Residues with 20% to 50% solvent
accessibility were considered to be moderately accessible andthese residues were mutated only if a naturally occurring
DENV-2 substitution was identified at that site (see below).
Greater than 50% accessibility was considered highly accessible
and all the residues that fell into this category were mutated.
VIPERdb (Shepherd et al., 2006) was used to confirm that
residues calculated to be solvent accessible by GETAREA 1.1
were also accessible on the surface of the virus based on the
cryo-EM model of the mature DENV-2 virion (PDB-ID: 1THD)
(Zhang et al., 2003).
The ED3 sequence (residues 295–395 of E) of 50 DENV-2
strains were aligned in order to identify amino acid substitutions
of surface accessible residues (according to the parameters
listed above) relative to DENV-2 strain NGC. These 50 DENV-
2 strains are representatives of all six of the currently described
DENV-2 genotypes (Rodriguez-Roche et al., 2005) and likely
represent the majority of surface accessible amino acid
sequence diversity within ED3 for DENV-2. A total of
seventeen naturally occurring substitutions were identified at
fourteen surface accessible residues (Fig. 4) and these were
individually incorporated into the rED3. In addition, 16
conserved residues were identified (Fig. 4) as being highly
surface accessible and were subjected to a combination of
glycine and alanine scanning mutagenesis, essentially to
remove the side chain of each residue. Initially, glycine
substitutions were used for all conserved residues, as well as
instances when there was a very conservative natural substitu-
tion. Glycine substitutions that resulted in greater than 4-fold
changes in MAb binding affinity for more than one of the MAbs
tested were also mutated to alanine to verify the results. The
reasoning for this approach was that glycines, with only a
hydrogen atom as a side chain, have more conformational
freedom than any other residue and could therefore increase the
conformational entropy in parts of the protein where they were
substituted (Branden and Tooze, 1999), which alone could
affect MAb binding affinity. This was thought to be a good
initial indicator for critical epitope residues as the affinity
change would potentially be more dramatic. In addition,
preliminary studies indicated that glycine substitutions of
surface residues were well tolerated in the rED3 based on
MAb affinity measurements. Alanine, however, is constrained
by a side chain and therefore does not have the same
conformational freedom as glycine and was used to verify
initial mapping of potential epitope residues based on a glycine
substitution.
The Kd of the seven DENV-2 type-specific MAbs was
determined by titration in an indirect ELISA with all 41 rED3
mutant proteins. Most amino acid substitutions had a relatively
minor effect on the binding affinity of all seven MAbs, having
less than a 4-fold change compared to the wild-type rED3
(Table 4). Those substitutions that resulted in a change in
binding affinity between 4- and 10-fold were defined as having
“weak” affects on the binding affinity. For MAb 3H5 mutants
D329E, P332G, and P332A fell into this category. With MAb
9F16 mutants K307G, E327G, and D329G had weak affects on
binding affinity. Only mutant P332G had a weak affect on the
binding affinity of MAb 2Q1899. Mutants M301A, P332G, and
P332A had weak affects on the binding affinity of MAb
Fig. 4. DENV-2 ED3 alignment of 11 representative strains compared to DENV-2 NGC. Naturally occurring amino acid substitutions and conserved residues which
were mutated to glycine/alanine are in bold and underlined. All the residues that were mutated are surface accessible residues on the DENV-2 virion. The DENV-2
NGC and DAKHD10674 sequences were done by the authors, the Malaysia 87a sequence is from Samuel et al. (1989), and the rest were acquired from GenBank;
16681 (U87411), Malaysia86 (X15433), Malaysia87b (X15434), PR159 (L10046), P81407 (AF231717), SriLanka85b (L10040), Taiwan87 (L10052), Thailand58
(D10514) and Trinidad53 (L10053).
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affinity of MAb 5C36 and no mutants fell into this category for
MAbs M8051122 and IP-05-143.
Mutations that resulted in a greater than 10-fold change in
binding affinity were considered to have “strong” affects. These
were M301G, K305G, K305A, E383G, P384G, and P384A. All
six of these had similar effects on binding affinity for the seven
MAbs tested (Table 4). Discrepancies in the results occurred
with mutants M301G and M301A, as well as E383G and
E383A. In these two cases there was a greater than 10-fold
decrease in binding affinity with the glycine mutant but no
change with the alanine mutant. This would imply that residues
M301 and E383 are not critical for the interaction of these
MAbs with ED3 but are still likely to be located on the
periphery of the epitope. MAb GTX77558 was an exception
and showed a weak decrease in binding affinity with mutant
M301A indicating that residue M301 may be more important
for the binding of this MAb to ED3.
Epitope analysis
Mutations M301G, K305G, K305A, E383G, P384G, and
P384A resulted in greater than 10-fold decreases in binding
affinity with all seven MAbs as compared to the wild-type
rED3. Residues M301, K305, E383, and P384 are found on two
adjacent loops and cluster relatively close to one another on the
upper lateral face of ED3 (Fig. 5a). As stated above, residues
M301 and E383 do not appear to be critical for MAb binding asM301A and E383A mutations had no effect on the binding
affinity of any of the MAbs with the exception of MAb
GTX77558, which showed weak loss of binding with mutant
M301A. Therefore, residues K305 and P384 are the critical
amino acids involved in the antigenic site of all seven MAbs
tested (Fig. 5a, shown in red).
Mutations that were considered to have “weak” affects on
binding of one or more of the seven MAbs were M301A,
K307G, E327G, D329E, D329G, P332G, and P332A. Conse-
quently, these residues are predicted to be located on the
periphery of the MAb epitopes (Fig. 5a, shown in pink).
Residues M301 and E383 are considered to be on the periphery
of the epitope for all seven MAbs as they are adjacent to other
critical residues and their affect on the binding affinity was
dependant on the substitution (Fig. 5a, shown in pink).
The epitope mapping data suggest that there are four
similar, overlapping, epitopes recognized by the seven DENV-
2 ED3 type-specific MAbs in this study that form one major
antigenic site. All four epitopes are composed of the same two
critical residues (K305 and P384) as well as two peripheral
residues (M301 and E383) but have distinct footprints on ED3
as evidenced by the variable “weak” loss of binding with
certain mutants (Fig. 5b). Peripheral residues for MAb 3H5
include D329 and P332 while for MAb 9F16 residues K307,
E327, and D329 are likely to be found on the periphery of the
epitope. MAbs 2Q1899, GTX77558, and 5C36 have residue
P332 on the periphery of the epitope they recognize. However,
for MAbs M8051122 and IP-05-143 no additional residues
Fig. 5. Predicted epitope for the seven MAbs in this study. (a) All the mutated residues are colored yellow. Residues K305 and P384 are predicted to form the center of
the epitope of all seven MAbs and are colored red. Residues M301 and E383 are predicted to be on the periphery of the epitope for all seven MAbs and are colored
pink. Different combinations of residues K307, E327, D329, and P332 are predicted to be on the periphery of subsets of the seven MAb epitopes and also are colored
pink. (b) There are predicted to be four overlapping epitopes recognized by the sevenMAbs and these epitopes center on the critical residues K305 and P384. The rings
represent the area predicted to be the footprint of each MAb or set of MAbs on the surface of ED3 as predicted by their interaction with peripheral residues. The 3H5
epitope is shown in blue and includes residues M301, E383, D329, and P332. The 9F16 epitope is shown in purple and includes residues M301, K307, E383, E327,
and D329. The epitope recognized by MAbs 2Q1899, GTX77558, and 5C36 is shown in gold and includes residues M301, E383, and P332. The epitope for MAbs
M8051122 and IP-05-143 is shown in green and includes residues M301 and E383. The diagrams are based on the crystal structure of the DENV-2 E protein (PDB-ID:
1OKE).
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they recognized.
Discussion
The goal of this study was to characterize the epitopes
recognized by seven DENV-2 ED3 type-specific MAbs. Site-
directed mutagenesis was employed to generate a panel of
DENV-2 NGC rED3 mutants containing single amino acidsubstitutions of surface accessible residues. The results obtained
reveal that the seven MAbs recognize overlapping epitopes that
form one antigenic site. It would appear that this antigenic site is
a dominant DENV-2 neutralization determinant, a concept that
is consistent with studies on other flaviviruses (Roehrig, 2003).
Previous studies have attempted to map the epitope of MAb
3H5 (Hiramatsu et al., 1996; Trirawatanapong et al., 1992) and
produced conflicting results. Our results partially agree with
those of Hiramatsu et al. (1996) who described a contiguous
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protein using a DENV infectious clone containing the prM and
E genes of DENV-2 NGC. Our results, however, indicate that
only residue P384 is a critical residue within the epitope, while
we predict that residue E383 is on the periphery of the epitope.
Also, using a very non-conservative G385E mutant rED3, we
saw no loss in binding affinity with MAb 3H5 indicating that
this residue is not part of the epitope. In addition, our results
indicate that the epitopes recognized by all seven MAbs,
including 3H5, are conformational as the critical residues (K305
and P384) for binding are located on adjacent, discontinuous
segments of ED3. Several additional residues are predicted to be
on the periphery of the MAb epitopes and indicate that their
footprints on ED3 cover at least three discontinuous segments.
These segments include a section of the N-terminal linker
region through a portion of β-strand A (residues 301–307),
parts of the BC loop region (residues 327–332), and FG loop
residues 383 and 384, which come together to form a single
antigenic site on the upper surface and lateral face of ED3. This
is consistent with data from studies with other flaviviruses,
namely WNV (Nybakken et al. 2005) and JEV (Wu et al.,
2003), and could indicate that similar type-specific neutralizing
epitopes exist on the equivalent surfaces of ED3 of DENV-1, -3,
and -4.
The antigenic site recognized by the MAbs in this study
seems to be highly conserved among DENV-2 strains and is,
therefore, a potentially very important component of candidate
DENV-2 vaccines. Surprisingly, only 1 of the 17 naturally
occurring rED3 mutants (D329E) affected MAb binding. This
mutation only resulted in a weak (4-fold) decrease in binding
affinity for one MAb (3H5). Conservation of this DENV-2 type-
specific antigenic site was confirmed by MAb 3H5, which was
used as a representative of the seven MAbs studied and was
shown to efficiently neutralize five different DENV-2 strains
with very similar PRNT50 concentrations. One of these strains,
DAKHD10674, contains the D329E mutation that caused a
weak decrease in affinity of MAb 3H5 for the rED3. This
verifies our assessment of the substitution of residues deemed to
be critical epitope residues and those considered to be on the
periphery. The overall conservation of this antigenic site may
indicate its importance as a functional epitope for the virus.
The initial attachment of DENV and other flaviviruses to
mammalian and mosquito cell lines, in-vitro, has been shown to
depend on cell surface glycosoaminoglycans, in particular
heparan sulfate (Chen et al., 1997; Hung et al., 1999). Soluble
heparin has been shown to block the binding of DENV-2 ED3 to
BHK21 cells, which suggests that ED3 binds to cell surface
heparan sulfates (Hung et al., 2004). The putative heparan
sulfate binding site on the DENV-2 ED3 includes residues
K305, K307, and K310 (Hung et al., 2004). Therefore, one
proposed mechanism of neutralization by the DENV-2 type-
specific MAbs used in this study is by blocking ED3 attachment
to cell surface heparan sulfates as a result of MAb binding to
residue K305 by all seven MAbs, and also to K307, which was
predicted to be on the periphery of the epitope of MAb 9F16.
Heparin, however, was not shown to block the binding of ED3
to C6/36 mosquito cells, but a DENV-2 E peptide comprisingresidues 380–389 of ED3 did (Hung et al., 2004). Since our
predicted epitope for the seven MAbs tested includes residue
P384, it would follow that these MAbs would also block
attachment of ED3 to a yet unidentified mosquito cell receptor
as well. Thus, the location of the antigenic site recognized by all
seven DENV-2 MAbs in this study supports a mechanism of
neutralization that, at least in part, entails blocking of attach-
ment to cell receptor.
Our results indicate that, as the available ED3 binding sites
on the virion are saturated by MAb, neutralization of virus
infectivity approaches 100%. Virus neutralization was observed
to increase incrementally as a result of increased MAb
occupancy of ED3, which implies that occupancy levels
below 100% probably reduce the propensity of individual
virus particles to successfully infect susceptible cells. This is
most likely due to competition between MAbs and cell surface
receptors for binding to ED3 on virions since neutralizing Mabs
against ED3 have been shown to efficiently block virus
adsorption to susceptible cells (Crill and Roehrig, 2001). In
addition, depending on the MAb, it is predicted that 10%–50%
relative occupancy of ED3 on the virion by MAb is necessary
for virus neutralization and for all seven MAbs occupancy
levels approaching saturation were required for 100% neutra-
lization of virus infectivity. This corresponds to a multi-hit
mechanism of neutralization, which has been described for
several other viruses including rabies virus (Flamand et al.,
1993), poliovirus (Icenogle et al., 1983), rhinovirus (Smith et
al., 1993), adenovirus (Stewart et al., 1997), papillomavirus
(Booy et al., 1998), and influenza virus (Taylor et al., 1987).
Variability was seen between the MAbs with respect to the
relative occupancy levels predicted to neutralize particular
percentages of virus infectivity (Table 3). This was significant
as all seven MAbs recognize overlapping epitopes that form one
antigenic site on ED3. Although four overlapping epitopes were
identified by the seven MAbs, the differences in occupancy
levels required for neutralization of virus infectivity did not
necessarily correlate with MAbs that recognized similar
epitopes. This implies that there are inherent differences
between the interactions of MAbs with ED3 that allow some
to neutralize more effectively at lower relative occupancy
levels. This is especially true for MAb 5C36, which neutralized
the majority of virus infectivity over a relatively narrow range of
occupancies (50%–94%) compared to the other six MAbs yet
all had similar affinities for virion-associated ED3. Clearly,
more studies are necessary to understand the mechanism of
neutralization of DENV-2.
An improved understanding of the neutralization mechanism
of DENV-2 by anti-ED3 antibodies will allow for a vaccine
design that will elicit the most potent neutralizing antibody
responses. In this study four overlapping neutralizing epitopes
were identified that appear to form a single, dominant, antigenic
site on ED3 that is conserved among DENV-2 strains. The
relative occupancy of this antigenic site by MAbs was
correlated with neutralization of virus infectivity and indicated
that anti-ED3 type-specific MAbs neutralized virus particles
primarily by saturating available ED3 binding sites. Overall,
designing a vaccine that elicits antibodies to this dominant
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humans would be advantageous and could be expected to
protect against all known DENV-2 strains.
Materials and methods
Cells and viruses
Monkey kidney Vero cells were maintained at 37 °C in a 5%
CO2 incubator in Dulbecco's modified essential media
(DMEM) containing 8% fetal bovine serum (FBS). Mosquito
C6/36 cells were maintained at 28 °C in DMEM containing 10%
FBS and supplemented with tryptose phosphate buffer. The
DENV strains used in this study were DENV-2 New Guinea C
(NGC), S16803, DAKHD10674, DAKAR578, H8-2027, and
IB-H11208 (Table 2). Primary virus stocks were passaged twice
in C6/36 mosquito cells to obtain sufficient titers.
Purification of virus
C6/36 mosquito cells were grown in a 850 cm2 roller bottle
and infected with DENV-2 NGC at an MOI of approximately
0.1. The cell infected supernatant was harvested on day 7 post
infection. Cell debris was removed by centrifugation at
5000 rpm for 30 min at 4 °C. The supernatant was layered
on top of a 30% sucrose solution containing 10 mM Tris,
100 mM NaCl, and 1 mM EDTA. The virus was pelleted by
ultracentrifugation in a swinging bucket rotor at 26,000 rpm
for 4 h at 4 °C to remove low molecular weight contaminants
such as soluble proteins. The supernatant was poured off and
the tubes were briefly left upside down on chromatography
paper in order to remove excess liquid from the side of the
tubes. The virus pellet was resuspended in PBS. The infectious
titer was determined by a standard plaque assay on Vero cells.
The purity of the virus preparations was verified by SDS–
PAGE (data not shown).
MAbs
Seven commercially available MAbs were used in this study:
3H5 (Chemicon) (Gentry et al., 1982), M8051122 (Fitzgerald
Industries), 9F16 (US Biological), 2Q1899 (US Biological),
5C36 (US Biological), IP-05-143 (RayBiotech, Inc.), and
GTX77558 (GeneTex). All seven are affinity purified IgG1
mouse MAbs prepared against DENV-2.
Expression and purification of recombinant DENV-2 ED3
The region corresponding to ED3 of the DENV-2 strain New
Guinea C (NGC) was reverse transcription-PCR amplified for
cloning and expression as maltose binding protein (MBP)
fusions using the pMal-c2x system (New England Biolabs,
Beverly, MA). RNA extraction of virus infected cell culture
supernatant was done using Qiagen Viral RNA extraction Kit
(Qiagen). Reverse transcription-PCR was done using the Titan
Kit (Roche). The primers used (Forward: 5′-CGAGGGAA-
GGATTTCAAAAGGAATGTCATACTCTATG −3′ andReverse: 5′-GCCAAGCTTTCATCCTTTCTTAAACCAGTT-
GAGC-3′) were designed for cloning into the pMal-c2x vector
and contained XmnI and HindIII restriction sites respectively.
Appropriate primers were also designed for constructing rED3s
for DENV-1 strain OBS7690, DENV-3 strain H87, and DENV-
4 strain 703-4 and these gene fragments were also cloned into
pMal-c2x. The recombinant ED3s (rED3), comprising amino
acids 295–395 of the E protein tagged to MBP, was expressed
in Escherichia coli DH5α using a method similar to that
described previously by Li et al. (2005). Briefly, 20 mL
cultures of bacteria were grown in LB medium containing 50
μg/mL ampicillin to an OD600 of approximately 0.6 and
induced with 1 mM IPTG at 37 °C for 3 h. Bacterial cells
were pelleted and stored at −20 °C overnight. The following
day cells were lysed in 1 mL of MBP column buffer (20 mM
Tris–HCl, 200 mM NaCl, 1 mM EDTA) by freeze/thawing in
liquid nitrogen/37 °C waterbath. Lysates were centrifuged at
12,000 rpm at 4°C for 30 min and the supernatant was mixed
with 500 μL amylose resin (NEB) in a 1.5 mL eppendorf and
incubated at 4 °C on a rocker for 1 h. Tubes were centrifuged
at 3000 rpm for 1 min and the supernatant removed. The resin
was washed three times with 1 mL MBP column buffer and
bound protein was eluted twice with 500 μL of MBP column
buffer containing 10 mM maltose. Concentrations of proteins
were determined by spectrophotometric analysis.
Mutagenesis of recombinant DENV-2 ED3
Site-directed mutagenesis of the DENV-2 NGC ED3 gene
fragment in the pMal-c2x vector was done using the
Quickchange kit (Stratagene, La Jolla, CA) according to the
manufacturer's instructions.
Western blot
MAbs were initially tested for their reactivity with the
DENV-2 rED3 by Western blot. The DENV-2 rED3 was
expressed and extracted as described above. Crude bacterial
lysates were run out in a 10% SDS polyacrylamide gel for both
IPTG induced and uninduced (no expression of MBP tagged
rED3) samples. The gel was either stained with brilliant blue R
concentrate (Sigma) or transferred to a PVDF membrane for
subsequent Western blotting with the DENV-2 MAbs at a
dilution of 1/1000. Binding of these MAbs to the MBP tagged
rED3 was detected using HRP conjugated goat anti-mouse
immunoglobulins (Sigma) and detected using 3,3′-diamino-
benzidine enhanced liquid substrate system according to the
manufacturer's instructions (Sigma).
Indirect ELISA
An indirect ELISA was used to investigate the specificity of
the DENV-2 MAbs. Briefly, 200 ng of MBP tagged rED3s from
DENV-1 strain OBS7690, DENV-2 strain NGC, DENV-3 strain
H87, and DENV-4 strain 703-4, as well as MBP alone was
adsorbed to the wells of a 96-well microtiter plate in triplicate
for each MAb. The MAbs were tested at a concentration that
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addition, a DENV-2 polyclonal mouse immune ascitic fluid
(MIAF) was used as a positive control. The indirect ELISAwas
carried out in a similar manner to the affinity measurements by
indirect ELISA (see below) except that Mabs were tested for
binding at a single MAb concentration.
Plaque reduction neutralization test 50% (PRNT50)
MAbs were diluted to either 80 nM (GTX77558), or 160 nM
(3H5, M8051122, 9F16, 2Q1899, and IP-05-143), or 320 nM
(5C36) and then serially diluted 2-fold in MEM containing 2%
FBS to essentially cover the same range of concentrations as the
affinity ELISAonce dilutedwith an equal volume of virus. DENV-
2NGCwas diluted to approximately 1 pfu/μL inMEMcontaining
2% FBS. 400 μL of virus (∼400 pfu) was mixed with an equal
volume of MAb dilution or 400 μL of MEM containing 2% FBS
(control) and was incubated at room temperature (25 °C) for 1 h.
Following this incubation, 200 μL of each virus/MAb mixture, or
controls, was added in triplicate to wells of a 6-well plate
containing ∼80% confluent monkey kidney Vero cells. Infection
was allowed to take place for 1 h at room temperature at which
point the cells were washed twice with PBS, overlaid with MEM
containing 2%FBS and 1%Agar, and incubated at 37 °C. Plaques
were visualized on day 6 by staining with neutral red. PRNT data
were converted to percent neutralization relative to controls in the
absence of MAb and PRNT50 concentrations were calculated by
doing a non-linear regression analysis using Sigmaplot (Version
9.01, Systat Software, Inc., CA). The data are fitted by a standard
four parameter logistic curve (i.e. dose–response curve) by the
equation: y=min+(max−min) / (1+(x /EC50)slope factor). PRNT50
assays were carried out and analyzed in the same way for MAb
3H5 with DENV-2 strains S16803, DAKHD10674, DAKAR578,
H8-2027, and IB-H11208 in addition to NGC. The results are an
average of two experiments.
Affinity measurements by indirect ELISA with rED3
The wells of 96-well microtiter plates (Corning Inc., Corning,
NY) were coated with 200 ng of rED3 diluted in borate saline
pH 9.0 at 37 °C for 2 h. This amount of rED3 was determined to
saturate the wells by undertaking a checkerboard serial dilution
of anti-MBP antisera (NEB) and rED3, which yielded peak
absorbance values that were below the maximum range of the
plate reader (data not shown). Wells were washed twice with
distilled and deionized water (ddH2O) and blocked for 30 min at
room temperature (25 °C) with blocking buffer [phosphate-
buffered saline (PBS), 0.1% (v/v) Tween-20, 0.25% (w/v)
bovine serum albumin (BSA)] and subsequently washed twice
with ddH2O. The DENV-2 MAbs were diluted to either 40 nM
(GTX77558), or 80 nM (3H5, M8051122, 9F16, 2Q1899, IP-
05-143), or 160 nM (5C36) and added to duplicate wells
followed by 11 two-fold serial dilutions in blocking buffer. This
range of concentrations was determined to cover the full range of
binding, from undetectable binding to saturation, to the DENV-2
NGC rED3. Antibodies were allowed to bind overnight at room
temperature (25 °C) for 15–18 h. Subsequently, the microtiterplates were washed twice with ddH2O and twice with PBS-T
(PBS containing 0.1% Tween-20) followed by addition of a
1/1000 dilution of HRP conjugated goat anti-mouse immu-
noglobulins (Sigma) and incubated for 1 h at room temperature.
Following this incubation microtiter plates were washed twice
with ddH2O and twice with PBS-T. Antibody binding was
visualized by addition of 3,3′,5,5′-tetramethylbenzidene sub-
strate (Sigma). After 30 min of incubation at room temperature
the absorbance was read at 655 nm on a model 3550-UV plate
reader (Bio-Rad, Hercules, CA). Binding curves and Kd values
were determined by doing a non-linear regression analysis
using Sigmaplot (Version 9.01, Systat Software, Inc., CA). The
results are an average of two experiments.
Affinity measurements and estimates of occupancy by
antibody-sandwich ELISA with purified virus
The wells of a 96-well microtiter plate (Corning Inc.,
Corning, NY) were coated with 50 μL of a 1/5 dilution of
rabbit anti-DENV-ED3 polyclonal sera (“capture antibody”)
for 2 h at 37 °C. The plates were washed twice with PBS-T
and twice with ddH2O. Purified DENV-2 NGC (∼5×107
PFU/mL) was diluted 1/50 in blocking buffer and 50 μL was
added to each well and incubated at 37 °C for 2 h. The
remainder of the assay was undertaken as described above
with the rED3, except that the primary MAbs were only
incubated for 1 h at room temperature in accordance with the
length of incubation used for the virus neutralization assay.
The entire experiment was carried out in a biological safety
cabinet as the virus was presumed to be infectious throughout
the experiment. Binding curves and Kd values were
determined by doing a non-linear regression analysis using
Sigmaplot (Version 9.01, Systat Software, Inc., CA). The
results are an average of two experiments. Generation of
colored substrate, and thus the absorbance reading in the
indirect ELISA, is proportional to the amount of antibody
bound to antigen in the well. At saturation (i.e. maximum
absorbance) it is predicted that all possible ED3 binding sites
on the virion are occupied by MAb. Therefore, absorbance
readings below saturation can be calculated as fractional
occupancies of the total available ED3s by MAb.
Statistical analysis
The Kd values and PRNT50 concentrations are presented as
mean±standard error of the mean (SEM) and were analyzed
using SigmaStat (Version 3.1, Systat Software, Inc., CA).
Statistical analyses were done using one-way analysis of
variance (ANOVA) followed by a Bonferroni post hoc test
with Pb0.05 required for statistical significance.
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